HU-WXAT@EC2603A

WuXi AppTec Anticipates Revenue Growth of Approximately 15.84% in 2025

Macquarie Recommends Buying Shares of Wuxi Biologics and Wuxi Apptec

JPMorgan Increases Stake in WuXi Biologics to 7%

WuXi AppTec Announces 2025 Earnings Guidance, with a 41.33% Growth in Net Profit

JPMorgan Reduces Holding in WuXi Biologics by 798,119 Shares

Goldman Sachs Upgrades WuXi AppTec's A-Share Rating to Buy

WuXi Biologics Announces Strong 2025 Financial Forecast, Revenue and Net Profit Both Up

JPMorgan Cuts Stake in Wuxi Biologics by 2.517805 million Shares

WuXi Biologics Receives Multiple ESG Ratings and Certifications

WuXi AppTec Discloses Business Scale and Global Layout

WuXi AppTec Updates Business Progress at J.P. Morgan Healthcare Conference

WuXi Biologics Announces Latest Progress in GLP-1 Pipeline

WuXi Biologics to issue 584 million new H shares

WuXi Biologics Q4 Earnings Beat Expectations, CLSA Rates 'Outperform'

Wuxi Biologics Expected Net Profit Growth of 41.33% in 2025

JPM 44th Global Healthcare Conference Focuses on Biopharmaceutical Industry Trends

WuXi Biologics Announces 2024H Revenue with Minor Increase

CLSA Maintains Overweight Rating for Wuxi Biologics with Increased Target Price

Controlling Shareholders of Wuxi Biologics Completed the Share Reduction Plan

STARCOIN GROUP

AE LOGISTICS

GUANZE MEDICAL

WATER INDUSTRY

ZHONGSHI MINAN

IDT INT'L

HAIZHI TECH GP

MANY IDEA CLOUD

FIRST CAP GP

XL2CSOPCOIN-U

02359

02268

Macquarie's research report indicates that WuXi AppTec has been included in the U.S. 1260H list, but this list does not constitute an investment ban and mainly affects defense contracts. The report suggests that investors should buy WuXi AppTec during price corrections and maintains its "outperform" rating with a target price of 132 yuan. Meanwhile, WUXI XDC is also recommended with a target price of 73 yuan

AASTOCKS

WUXI APPTEC

WUXI XDC

Macquarie urges to buy WuXi AppTec, expected to be included in the US 1260H list without being affected

STECH

00HSI

00003

The Hang Seng Index closed at 27,032 points, down 233 points or 0.9%; the Hang Seng TECH Index reported 5,408 points, down 91 points or 1.7%. The total market turnover was HKD 238.705 billion. Meituan fell over 4%, and several heavyweight stocks such as Tencent and Alibaba also declined. WuXi AppTec, Sun Hung Kai Properties, Sinopec, China Resources Mixc Lifestyle, and HK & CHINA GAS reached new highs, with active trading

Hang Seng TECH Index

Hang Seng Index

HK & CHINA GAS

According to the "All-Day Express," the Hang Seng Index closed at 27,032 points, down 233 points; the Hang Seng TECH Index closed at 5,408 points, down 91 points. Meituan fell over 4%, while WuXi AppTec, Sun Hung Kai Properties, Sinopec, China Resources Vientiane Life, and HK & CHINA GAS reached new highs with active trading

00020

09899

03690

09961

MPNGY

603259

02269

The Hong Kong stock market was under pressure in the morning session, with the Hang Seng Index down 242 points, closing at 27,023 points. The National Index fell by 89 points, and the Hang Seng Tech Index dropped by 92 points. Technology stocks generally declined, with Trip.com, Meituan, and NetEase experiencing significant losses. SenseTime rose 5.2% against the trend. Market expectations for a Federal Reserve rate cut have cooled, leading to a slight decline of 66 points in the Dow Jones Industrial Average

SENSETIME-W

NETEASE MUSIC

MEITUAN

TRIP.COM-S

Meituan

WuXi AppTec

WUXI BIO

NTES-S

NetEase

"Hong Kong Stocks" Hang Seng Index fell 242 points in the half-day, with technology investment stocks leading the decline, while domestic property and WuXi AppTec stocks performed well

159892

520690

520500

159316

159992

159570

512290

Nomura expects WuXi AppTec's revenue in Q4 2025 to grow by 9.2% to RMB 11.7 billion, with net profit increasing by 142% to RMB 7.1 billion. For the fiscal year 2026, revenue is projected to grow by 16% to RMB 52.6 billion, and profit is expected to increase by 3% to RMB 19.6 billion. Revenue from TIDES and later-stage development and manufacturing businesses is expected to grow by 55% and 10%, respectively. The target price has been raised from HKD 132.8 to HKD 157.07, and the A-share target price has been increased from RMB 120.85 to RMB 142.93, both with a "Buy" rating

ChinaAMC Hang Seng Biotechnology Technology ETF(QDII)

Bosera Hang Seng SCHK Innovative Drug Select ETF

Huatai-PB Hang Seng Innovative Drugs Industry ETF(QDII)

Penghua CSI HK Connect Health Care Composite ETF

China Merchants CSI Biotechnology Theme ETF

ChinaAMC SSE Health Care ETF Initiating Fund

ChinaAMC CSI Biotechnology Theme ETF

GF CSI HK Innovative Drugs Industry ETF(QDII)

E Fund Hang Seng SCHK Innovative Drug ETF

Yinhua CSI Innovative Drugs Industry ETF

Hwabao WP Hang Seng SCHK Innovative Drug Select ETF

ChinaAMC SSE STAR Biology and Medicine ETF

E Fund CSI Biotechnology Theme ETF

Fullgoal Hang Seng SCHK Innovative Drug & Healthcare ETF

China Universal CNI HK Connect Innovative Drugs Industry ETF

Guotai CSI Bio-medicine ETF

Bosera Hang Seng Health Care ETF(QDII)

Nomura expects WuXi AppTec's revenue this year to exceed market expectations, raising the target price to 157.07 yuan

Goldman Sachs report indicates that the mainland healthcare sector will continue to be strong, but investors need to pay attention to the value of the R&D pipeline. Outperformance depends on key data and earnings visibility. Positive on CDMO companies, upgrading WuXi AppTec and WUXI XDC ratings to "Buy." A selective strategy is recommended for biotech and pharmaceutical companies, recommending SKB BIO-B, HENLIUS, and HANSOH PHARMA. The medical device sector maintains a neutral stance, recommending ANGELALIGN and WEIGAO GROUP. A cautious attitude is taken towards the medical services sector, downgrading HYGEIA HEALTH and JXR ratings

HANSOH PHARMA

SKB BIO-B

KELUN PHARMA

HENLIUS

WEIGAO GROUP

China Southern Hang Seng Biotech ETF(QDII)

Minsheng Royal CSI Biotechnology Theme ETF

Hwabao WP CSI Pharmaceuticals ETF

ICBCCS SSE STAR Biology and Medicine ETF

HYGEIA HEALTH

Founder Fubon CSI Medicine and Medical Device Innovation ETF

Penghua SSE STAR Biology and Medicine ETF

ANGELALIGN

Dacheng CSI All Share Health Care Equipment and Services ETF

Hwabao WP CSI Medical Service ETF

Huaan Hang Seng Biotech ETF

E Fund CSI 300 Health Care ETF

Ping An CSI Medicine and Medical Device Innovation ETF

Goldman Sachs: The mainland medical sector will rely more on data and profit visibility this year, optimistic about CDMO companies

09987

03288

00992

09660

00100

01772

01208

03993

00358

YUM CHINA(09987) rose 11.42%, with a trading turnover 1.1 Billion HKD, and a year-to-date rose 18.6%. HAITIAN FLAV(03288) rose 5.59%, with a trading turnover 394.2 Million HKD, and a year-to-date rose 3.8%. MINIMAX-WP(00100) fell 8.65%, with a trading turnover 675.2 Million HKD, and a year-to-date rose 194.5%. GANFENGLITHIUM(01772) fell 6.6%, with a trading turnover 1.2 Billion HKD, and a year-to-date rose 7.6%.

Top Gainers & Losers

YUM CHINA

HAITIAN FLAV

LENOVO GROUP

HORIZONROBOT-W

MINIMAX-WP

GANFENGLITHIUM

CMOC

JIANGXI COPPER

Top 5 HK Stock Gainers/Losers (>100B) (2.5)

RLAY

OpenAI's CEO Altman: The company may seek partners or invest in AI drug discovery

Wallstreetcn

Relay Therapeutics

Maxwealth CSI All Share Medical Apparatus and Instruments ETF

ALPS Medical Breakthrough

Lantern Pharma

YieldMax AI Option Income Strategy ETF

Invesco Biotechnology & Genome ETF

iShares US Medical Devices

Yinhua CNI HK Connect Innovative Drugs ETF

Recursion Pharmaceuticals

Abcellera Biologics

Tempus AI

China Universal NASDAQ Biotechnology Technology ETF(QDII)

Invesco Nasdaq Biotechnology ETF

iShares Genomics Immunology and Healthcare ETF

ChinaAMC CSI All Share Health Care Devices ETF

Exact Sciences

Marinus Pharma

iShares US Pharma

Tianhong CNI BIOMEDICINE ETF

VanEck Biotech ETF

iShares US Healthcare Providers

Ark Genomic Revolution ETF

SPDR S&P Health Equip

PHARMARON

Neumora Therapeutics

Absci

Health Care Select Sector SPDR

Moderna

VG Health

159987

688235

01093

The State Council has announced the newly revised "Regulations for the Implementation of the Drug Administration Law," which will take effect on May 15, 2026. This is the first comprehensive revision of the regulations in over twenty years. The key points of the revision include: improving the drug registration system, establishing exclusive market periods for pediatric drugs and drugs for rare diseases for the first time (up to 2 years and 7 years respectively), clarifying four new drug expedited approval pathways; strengthening the responsibilities of online drug trading platforms and regulating online drug sales; allowing segmented commissioning of innovative drug production to optimize the industrial supply chain; and shifting the regulatory focus from enterprises to drug marketing authorization holders, enhancing lifecycle supervision

- On January 27, Premier Li Qiang signed a decree announcing the revised Implementation Regulations of the Drug Administration Law, effective May 15, 2026.  
- The updated regulations, marking the first comprehensive revision in over 20 years, enhance drug research, approval processes, and production management, while emphasizing innovation and public access to safe medications.  
- Key changes include support for pediatric and rare disease drug exclusivity periods, stringent online sales regulations, and the introduction of a segmented production system to boost production efficiency.

Yinhua CSI Research Sector 100 ETF

BeOne Medicines

CSPC PHARMA

JD HEALTH

CSPC Innovation

Pharmaron

Beigene

Guotai SSE STAR Brand Name Drug ETF

Tigermed

SINO BIOPHARM

New Drug Administration Implementation Regulations Released: Allowing Innovative Drugs to be Produced in Segments, Accelerating the Market Launch of Good Medicines

03696

02228

INSILICO fell 11.58%; Jingtao Holdings fell 6.23%, with a transaction volume of HKD 792 million; WuXi Biologics fell 3.36%, with a transaction volume of HKD 442 million; WuXi AppTec fell 0.96%, with a transaction volume of HKD 323 million; WuXi Huilian fell 3.71%, with a market value of HKD 83.2 billion

HK Stock Movers Tracker

INSILICO

XTALPI

Hong Kong Stock Movement: INSILICO approved by FDA but fell 11.58%, leading stocks in the life sciences sector under pressure

09992

03986

02259

01055

02628

01276

01211

00981

00763

POP MART(09992) rose 9.07%, with a trading turnover 5.9 Billion HKD, and a year-to-date rose 5.1%. GIGADEVICE(03986) rose 5.52%, with a trading turnover 532.3 Million HKD, and a year-to-date rose 88.9%. HENGRUI PHARMA(01276) fell 4.36%, with a trading turnover 161.0 Million HKD, and a year-to-date rose 3.2%. WUXI APPTEC(02359) fell 4.13%, with a trading turnover 672.1 Million HKD, and a year-to-date rose 15.2%.

- The Hang Seng Index decreased by 0.29%, with a year-to-date increase of 3.3%; the Hang Seng Tech Index dropped by 1.16%, also with a 3% rise this year.  
- Pop Mart (09992) rose by 9.07%, achieving a trading volume of 5.88 billion HKD and a year-to-date increase of 5.1%.  
- In contrast, companies like Innovent Biologics (01276) and WuXi AppTec (02359) saw declines of 4.36% and 4.13% respectively, with year-to-date increases of 3.2% and 15.2%.

HU-WXAT@EC2603A(29171.HK)

Macquarie urges to buy WuXi AppTec, expected to be included in the US 1260H list without being affected

"Hong Kong Stocks" Hang Seng Index fell 242 points in the half-day, with technology investment stocks leading the decline, while domestic property and WuXi AppTec stocks performed well

Nomura expects WuXi AppTec's revenue this year to exceed market expectations, raising the target price to 157.07 yuan

Goldman Sachs: The mainland medical sector will rely more on data and profit visibility this year, optimistic about CDMO companies